NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
Following two phase 2a studies that were conducted by TOPIGEN with TPI 1020 in patients with asthma and COPD, NicOx and TOPIGEN had recently been in active discussions to explore potential new opportunities for the development of TPI 1020 in a variety of respiratory indications. As a result of the strategic review of Pharmaxis and TOPIGEN’s development pipeline, they have decided not to move forward with the development of TPI 1020.
The licensing and co-development agreement between NicOx and TOPIGEN on TPI 1020, a novel anti-inflammatory drug-candidate for respiratory indications, was signed in October 2005.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.